Thermo Fisher Scientific Inc. $TMO Shares Bought by Nichols & Pratt Advisers LLP MA

Nichols & Pratt Advisers LLP MA increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 47,615 shares of the medical research company’s stock after buying an additional 1,629 shares during the quarter. Thermo Fisher Scientific comprises approximately 1.4% of Nichols & Pratt Advisers LLP MA’s holdings, making the stock its 22nd largest position. Nichols & Pratt Advisers LLP MA’s holdings in Thermo Fisher Scientific were worth $23,872,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. J. Stern & Co. LLP lifted its holdings in Thermo Fisher Scientific by 58,006.4% in the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after acquiring an additional 31,455,105 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth approximately $15,501,867,000. Corient Private Wealth LP acquired a new stake in Thermo Fisher Scientific during the second quarter valued at approximately $382,547,000. Norges Bank bought a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $3,072,744,000. Finally, Bank of New York Mellon Corp acquired a new position in Thermo Fisher Scientific in the second quarter worth approximately $1,974,561,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $621.87 on Friday. The stock’s fifty day simple moving average is $558.64 and its 200-day simple moving average is $512.08. The company has a market capitalization of $229.94 billion, a price-to-earnings ratio of 33.45, a P/E/G ratio of 2.53 and a beta of 0.85. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $647.00.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same period last year, the company posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Insider Transactions at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president directly owned 14,784 shares in the company, valued at $9,064,366.08. The trade was a 43.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 275 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $627.05, for a total value of $172,438.75. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at $77,707,171.25. This represents a 0.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,768 shares of company stock worth $44,122,820 in the last ninety days. Company insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

TMO has been the subject of several research reports. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research note on Monday, July 6th. Wells Fargo & Company reduced their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Piper Sandler increased their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a research report on Monday, July 27th. Morgan Stanley upped their price objective on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Finally, KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.